GlycoCLICK™-based Nicotinamide Phosphoribosyltransferase Inhibitor Development Service

GlycoCLICK™-based Nicotinamide Phosphoribosyltransferase Inhibitor Development Service

Your Reliable Partner for Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitor Development

CD BioGlyco screens Enzyme Inhibitors by rapidly constructing libraries of various compounds through click chemistry, including Mannosyltransferase Inhibitors, NMPRTase inhibitors, O-GlcNAcase Inhibitors, Glycosidase Inhibitors, etc. The NMPRTase primarily converts nicotinamide to nicotinamide mononucleotide (NMN). NMN adenylyltransferase (NMNAT) further converts NMN to nicotinamide adenine dinucleotide, which is used in various physiological activities. Studies have found its association with cancer-related cell signaling processes. We provide a high-quality NMPRTase inhibitor development service to meet the needs of our clients in cancer research and other areas. Our comprehensive project management system ensures the efficiency and high-quality delivery of NMPRTase inhibitor development projects.

Several effective NMPRTase inhibitors have been developed. Click chemistry is a convenient method for assembling fragment-based inhibitors due to its efficient reaction properties and high modularity. We develop NMPRTase inhibitors by various click chemistry reactions. Based on computer-aided design, high-throughput screening capabilities, and click chemistry, we simplify the synthesis and screening process of enzyme inhibitors. Our development strategy is mainly as follows:

  • We use copper-catalyzed cycloadditions between azides and alkynes to construct triazole analogs and screen them for efficient and selective inhibitors.
  • We synthesize various other compound libraries by other click chemistry reactions and screen them for NMPRTase inhibitors with efficient inhibitory activity.
  • Based on the mechanism of action of NMPRTase, we develop corresponding competitive inhibitors, and non-competitive inhibitors through click chemistry.

Development strategies for NMPRTase inhibitors.

Publication Data

Technology: In silico drug discovery

Journal: Pharmaceuticals

IF: 4.6

Published: 2022

Results: In this study, starting from a high-throughput virtual screening approach, two additional chemical scaffolds acting as NMPRTase inhibitors were identified and annotated. These compounds synthesized by the assay showed good inhibitory activity. This study provides an effective idea for the development of NMPRTase inhibitors.

Fig.1 In vitro screening of the NMPRTase inhibitors.Fig.1 Results of the in vitro screen for NMPRTase inhibitors. (Ghanem, et al., 2022)

Applications

  • NMPRTase inhibitors are used to evaluate the site of action of NMPRTase in vivo.
  • NMPRTase is recognized as an attractive breakthrough point for the development of novel anticancer therapies and drugs. NMPRTase inhibitors are used in anticancer-related research.
  • NMPRTase inhibitors are used to study the function of NMPRTase in various physiological activities such as signal transduction.

Advantages of Us

  • We provide our clients with professional cutting-edge consulting and fully integrated enzyme inhibitor development programs.
  • We have assembled an experienced R&D team to better serve our clients.
  • Passion for our clients and the quest for click chemistry and enzyme inhibitor development is what keeps us going.
  • We continue to innovate and improve our click chemistry-related services to enhance the effectiveness of our R&D efforts.

CD BioGlyco is constantly expanding its technology to improve its ability to utilize click chemistry. We provide high-quality custom synthesis services for life sciences, drug discovery, etc. Please feel free to contact us for more information about NMPRTase inhibitor development. All you need to do is to tell us the purpose of your experiment. We will complete the whole process of program design, synthesis, screening, etc.

Reference

  1. Ghanem, M.S.; et al. Identification of NAPRT inhibitors with anti-cancer properties by in silico drug discovery. Pharmaceuticals. 2022, 15(7): 848.
For research use only. Not intended for any clinical use.
Related Services

Unleash the full potential of glycochemistry research with CD BioGlyco, the top CRO company committed to advancing the understanding of glycobiology through tailored solutions and exceptional expertise.

Copyright © CD BioGlyco. All Rights Reserved.
Top